At NINGBO INNO PHARMCHEM CO.,LTD., we pride ourselves on supplying critical components for the pharmaceutical industry, and 7-Xylosyltaxol (CAS 90332-66-4) stands out as a prime example. Derived from natural sources, this compound exemplifies the importance of high-purity natural product standards in driving innovation within pharmaceutical research and development.

The intrinsic value of 7-Xylosyltaxol lies in its meticulous purification and characterization, ensuring it meets the demanding criteria for pharmaceutical standards and reference materials. As a Paclitaxel derivative, it possesses a well-defined chemical structure and properties, making it indispensable for researchers engaged in drug efficacy studies, quality control, and analytical method development. The precise nature of 7-Xylosyltaxol CAS 90332-66-4 antineoplastic activity allows for consistent benchmarking in scientific investigations.

Our commitment as a supplier in China is to provide the global research community with compounds that not only meet but exceed expectations. The availability of 7-Xylosyltaxol supports a wide range of applications, from early-stage anticancer drug discovery to the validation of advanced analytical techniques. Its role in advancing pharmacological research is undeniable, offering a reliable benchmark for complex experiments.

For those looking to buy 7-Xylosyltaxol, understanding its contribution to the field of pharmaceutical standards and reference materials is key. It empowers scientists to achieve greater accuracy and confidence in their findings, whether they are exploring the 7-Xylosyltaxol CAS 90332-66-4 antineoplastic activity or developing sophisticated immunoassay development for Paclitaxel. The price reflects the intensive research and quality control involved in its production.

By consistently delivering high-quality natural product derivatives, NINGBO INNO PHARMCHEM CO.,LTD. aims to accelerate the pace of scientific discovery. 7-Xylosyltaxol is more than just a chemical compound; it is a vital enabler of progress in understanding and combating complex diseases, reinforcing our position as a trusted partner in the pharmaceutical supply chain.